Abstract Library

#4283 Long-term efficacy and safety of peptide receptor radionuclide therapy (PRRT) in Japanese patients with unresectable neuroendocrine tumour: Japanese phase I and phase I/II extension study

Introduction: PRRT with 177Lu-DOTATATE has been approved in Japan according to Japanese phase I and Phase I/II clinical trials. Primary end point of these clinical studies was safety and response rate, therefore, long-term efficacy and safety of PRRT for Japanese patients with NET are uncertain.

Conference:

Presenting Author: Ichikawa Y

Authors: Kobayashi N, Ono H, Okubo N, Akahoshi K, Kudo A,

Keywords: Neuroendocrine tumour, Peptide receptor radionuclide therapy, Japanese patients,

#3982 Safety and efficacy of peptide radionuclide therapy (PRRT) with 177Lu-DOTATATE for Japanese patients with neuroendocrine neoplasm (NEN): A single-center retrospective study

Introduction: After the approval of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in Japan (June 2021), its treatment experience is increasing, but limited data are available in Japanese patients with neuroendocrine neoplasm (NEN).

Conference:

Presenting Author:

Authors: Okamoto K, Hijioka S, Goto Y, Honma Y, Hirano H,

Keywords: PRRT, 177Lu-DOTATATE, Japanese cohort,

#3700 A prospective, multicenter, single-arm, open-label, phase 3 study of Lanreotide Autogel (LAN) in Chinese patients with unresectable, locally advanced or metastatic grade 1 or 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Introduction: The efficacy of LAN has been demonstrated for the treatment of GEP-NETs and associated symptoms in Caucasian (CLARINET; NCT00353496) and Japanese patients but is yet to be explored in the Chinese population.

Conference:

Presenting Author:

Authors: Lu M, Li E, Cao D, Chen J, Zhang N,

Keywords: neuroendocrine, neuroendocrine tumor, efficacy, safety,

#3351 Safety and efficacy of peptide receptor radionuclide therapy with 177 Lu-DOTA 0-Tyr 3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors

Introduction: Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA0-Tyr3-octreotate (177Lu-DOTATATE) is one of the most reliable treatments for unresectable, progressive neuroendocrine tumors (NETs) with somatostatin receptor expression.

Conference:

Presenting Author:

Authors: Kobayashi N, Takano S, Ito K, Sugiura M, Ogawa M,

Keywords: Peptide receptor radionuclide therapy, 177Lu-DOTA0-Tyr3-octreotate, neuroendocrine tumor,

#2167 Evaluation of Streptozocin-Based Chemotherapeutic Regimens for Advanced Pancreatic Neuroendocrine Tumors: A Multi-Center Clinical Study in Japan

Introduction: Streptozocin (STZ) has been used as a key drug against advanced pancreatic neuroendocrine tumors (pNETs). The standard in many countries is a daily STZ regimen combined with 5-fluorouracil administered once daily for 5 days every 6 weeks. However, in Japan, STZ was only covered by insurance beginning in 2015, and STZ is often used as monotherapy, as either a daily or a weekly regimen. There are few reports on STZ monotherapy for pNETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Sakamoto Y, Hijioka S, Shibuya H, Ito T, Imamura M,

Keywords: Streptozocin, pNETs,